Alpine Immune Sciences, Inc. - ALPN STOCK NEWS

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has granted Dr. Andrew S. Sandler an option to purchase 160,000 shares of common stock as part of his appointment as Chief Medical Officer. The option vests 25% after one year and the remaining 75% monthly over three years. It has a ten-year term and an exercise price of $8.38. If a change of control occurs within 12 months and results in termination, the option will fully vest. This grant is consistent with Nasdaq’s guidelines and aims to incentivize Dr. Sandler’s tenure at Alpine.

Alpine Immune Sciences (NASDAQ: ALPN) reported a productive second quarter for 2022, highlighting promising clinical data for its autoimmune and immuno-oncology candidates. ALPN-303 demonstrated enhanced potency against B cell cytokines with encouraging tolerability. The company removed a clinical hold on the NEON-2 trial of davoceticept, and plans to report initial data later this year. Financially, Alpine recorded a net loss of $18.1 million and $5.3 million in collaboration revenue. As of June 30, 2022, cash resources totaled $201.2 million, expected to last into 2024.

Evotec SE and Alpine Immune Sciences have expanded their partnership to develop a commercial manufacturing process for ALPN-303, a dual BAFF/APRIL inhibitor. This collaboration builds on their ongoing first-in-human program initiated in 2020, with Evotec providing drug substance materials for clinical studies. The enhanced contract will utilize Evotec's J.DESIGN technology platform in Redmond, Washington, aiming to improve outcomes for patients with systemic lupus erythematosus and other autoimmune diseases.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its participation in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The event is scheduled for August 10, 2022, at 4:05 p.m. ET. A live webcast will be accessible on the company’s investor relations website, with a replay available for 90 days post-event. Alpine focuses on developing innovative immunotherapies for cancer and autoimmune diseases, boasting a strong pipeline and strategic global collaborations.

Alpine Immune Sciences (NASDAQ:ALPN) has appointed Jörn Drappa, MD, PhD to its Board of Directors, bringing over 20 years of leadership in clinical development for autoimmune diseases. Dr. Drappa successfully led the R&D at Viela Bio and was integral in its $3.1 billion acquisition by Horizon Therapeutics. His expertise is expected to enhance Alpine's clinical pipeline, particularly for the drug ALPN-303, aimed at treating systemic lupus erythematosus and other inflammatory conditions. Concurrently, Jay Venkatesan, MD has stepped down from the board.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) has appointed Dr. Andrew S. Sandler as its Chief Medical Officer, effective August 17, 2022. Dr. Sandler joins from Kiadis Pharma and brings over 25 years of clinical and industry experience. His role will involve advancing multiple development programs targeting oncology and autoimmune diseases, including therapies like acazicolcept and davoceticept. President Stanford Peng expressed enthusiasm for Dr. Sandler's appointment, highlighting his extensive expertise in developing therapies for critical health conditions.

Alpine Immune Sciences (NASDAQ:ALPN) presented data on ALPN-303, a dual BAFF/APRIL antagonist, at the EULAR European Congress of Rheumatology. The compound shows high affinity binding, differentiating it from existing inhibitors. Preliminary results from a phase 1 study indicate promising pharmacodynamic reductions in circulating immunoglobulins among healthy volunteers. ALPN-303 targets severe autoimmune diseases, notably systemic lupus erythematosus. Future phase 2 studies are anticipated by the end of 2022.

Alpine Immune Sciences (NASDAQ: ALPN) announced its abstracts acceptance for presentation at the EULAR Annual Congress in Copenhagen (June 1-4, 2022) and the ASCO Annual Meeting in Chicago (June 3-7, 2022). Key highlights include the presentation of ALPN-303's preclinical data and preliminary Phase 1 data, showcasing its efficacy in inhibiting pathogenic autoantibodies. Additionally, updates on Davoceticept (ALPN-202) as a monotherapy and its combination studies with pembrolizumab will be discussed.

Alpine Immune Sciences (NASDAQ: ALPN) announced that the FDA has lifted the partial clinical hold on its NEON-2 trial investigating davoceticept (ALPN-202). This first-in-class drug, used with pembrolizumab, targets advanced malignancies. The hold was removed following a review of the safety database and protocol adjustments. The NEON-1 study continues unaffected. Previously, only enrolled patients received the drug while new participants were on hold. Alpine aims to advance its cancer immunotherapy pipeline with ongoing and future trials.